2. Search Result
Search Result
Results for "

anticonvulsant effect

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

2

Peptides

6

Natural
Products

7

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103230
    IEM-1460

    		iGluR Neurological Disease
    IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo .
    IEM-1460
  • HY-B0184
    Felbamate
    1 Publications Verification

    W-554; ADD-03055

    		 iGluR Neurological Disease
    Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
    Felbamate
  • HY-U00315S
    Gidazepam-d5

    Gidasepam-d5; Hidazepam-d5; Hydazepam-d5

    		 GABA Receptor Neurological Disease
    Gidazepam-d5 is a deuterium labeled Gidazepam. Gidazepam is an agonist of GABA receptor channels (GABA RCs), and has anticonvulsant effect .
    Gidazepam-d5
  • HY-W013378
    Carbamazepine 10,11-epoxide

    		Endogenous Metabolite Neurological Disease
    Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
    Carbamazepine 10,11-epoxide
  • HY-133773
    Desoxochlordiazepoxide

    		Biochemical Assay Reagents Neurological Disease
    Desoxochlordiazepoxide is a kind of benzodiazepine compound. Desoxochlordiazepoxide has anticonvulsant effect .
    Desoxochlordiazepoxide
  • HY-125555
    Azosulfamide

    		Bacterial Infection Neurological Disease
    Azosulfamide has an anticonvulsant effect and can be used for research of epilepsy. Azosulfamide is active against recurrent tetanus .
    Azosulfamide
  • HY-B0184A
    Felbamate hydrate

    W-554 hydrate; ADD-03055 hydrate

    		 iGluR Neurological Disease
    Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
    Felbamate hydrate
  • HY-107323
    Bentazepam

    QM 6008; Thiadipone; Tiadipone

    		 GABA Receptor Neurological Disease
    Bentazepam (Thiadipone) is a compound with short-action anxiolytic effect. Bentazepam shows anticonvulsant and sedative properties. Bentazepam can be used for the research of depressive disorder and anxiety .
    Bentazepam
  • HY-107323A
    Bentazepam hydrochloride

    QM 6008 hydrochloride; Thiadipone hydrochloride; Tiadipone hydrochloride

    		 GABA Receptor Neurological Disease
    Bentazepam (QM 6008, Thiadipone) hydrocholide is a compound with short-action anxiolytic effect. Bentazepam hydrocholide shows anticonvulsant and sedative properties. Bentazepam hydrocholide can be used for the research of depressive disorder and anxiety .
    Bentazepam hydrochloride
  • HY-B0184R
    Felbamate (Standard)

    W-554 (Standard); ADD-03055 (Standard)

    		 iGluR Neurological Disease
    Felbamate (Standard) is the analytical standard of Felbamate. This product is intended for research and analytical applications. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
    Felbamate (Standard)
  • HY-P1132
    Galanin (1-29)(rat, mouse)

    		Neuropeptide Y Receptor Neurological Disease
    Galanin (1-29)(rat, mouse) is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3 respectively. Anticonvulsant effect .
    Galanin (1-29)(rat, mouse)
  • HY-P1132A
    Galanin (1-29)(rat, mouse) TFA

    		Neuropeptide Y Receptor Neurological Disease
    Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect .
    Galanin (1-29)(rat, mouse) TFA
  • HY-B0184S1
    Felbamate-d5

    Felbamyl-d5; Felbatol-d5; Taloxa-d5

    		 iGluR Neurological Disease
    Felbamate-d5 is the deuterium labeled Felbamate[1]. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA)[2][3].
    Felbamate-d5
  • HY-B0184S
    Felbamate-d4

    		iGluR Neurological Disease
    Felbamate-d4 (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
    Felbamate-d4
  • HY-N8303
    Gardenin A

    		ERK PAK Neurological Disease Inflammation/Immunology
    Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .
    Gardenin A
  • HY-147377
    N-Salicyloyltryptamine

    		Calcium Channel ERK Potassium Channel Guanylate Cyclase NF-κB Cardiovascular Disease Neurological Disease Inflammation/Immunology
    N-Salicyloyltryptamine acts on voltage-dependent Na +, Ca 2+, and K + ion channels inhibitor. N-Salicyloyltryptamine inhibits K + currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect - .
    N-Salicyloyltryptamine
  • HY-141795
    Posovolone

    Co 134444

    		 Others Neurological Disease
    Posovolone (Co 134444) is an orally active, neuroactive steroid. Posovolone has anticonvulsant and anxiolytic-like activity as well as ataxic effects .
    Posovolone
  • HY-103234
    GYKI 52466

    		iGluR Neurological Disease
    GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .
    GYKI 52466
  • HY-103234B
    GYKI 52466 hydrochloride

    		iGluR Neurological Disease
    GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .
    GYKI 52466 hydrochloride
  • HY-103234A
    GYKI 52466 dihydrochloride

    		iGluR Neurological Disease
    GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
    GYKI 52466 dihydrochloride
  • HY-W013378S
    Carbamazepine 10,11 epoxide-d2

    		Endogenous Metabolite Isotope-Labeled Compounds Others
    Carbamazepine 10,11 epoxide-d2 is the deuterium labeled Carbamazepine 10,11 epoxide[1]. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures[2].
    Carbamazepine 10,11 epoxide-d2
  • HY-123335A
    L-796778 acetate

    		Somatostatin Receptor Neurological Disease
    L-796778 is a selective agonist of the sst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 is a partial agonist that inhibits Forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM. L-796778 has anticonvulsant effect .
    L-796778 acetate
  • HY-W013378R
    Carbamazepine 10,11-epoxide (Standard)

    		Endogenous Metabolite Neurological Disease
    Carbamazepine 10,11-epoxide (Standard) is the analytical standard of Carbamazepine 10,11-epoxide. This product is intended for research and analytical applications. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
    Carbamazepine 10,11-epoxide (Standard)
  • HY-W097106
    (S)-3-N-Cbz-Amino-succinimide

    		Drug Isomer Neurological Disease
    (S)-3-N-Cbz-Amino-succinimide (Compound 1d) is an antiepileptic agent that can inhibit pentylenetetrazole (PTZ) and maximal electroshock (MES)-induced tonic convulsions in mice .
    (S)-3-N-Cbz-Amino-succinimide
  • HY-P3960
    (Glu2)-TRH

    		Thyroid Hormone Receptor Endogenous Metabolite Neurological Disease
    (Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS .
    (Glu2)-TRH
  • HY-110289
    (R)-Citalopram oxalate

    		Serotonin Transporter 5-HT Receptor Neurological Disease
    (R)-Citalopram oxalate is an anticonvulsant, antidepressant and muscle relaxant. (R)-Citalopram oxalate is at least 20-fold weaker than S-citalopram (Escitalopram; HY-14258) as inhibitor of the 5-HT transporter (SERT). (R)-Citalopram oxalate functionally antagonises S-citalopram in vivo and in vitro. (R)-Citalopram oxalate has an effect on the association of Escitalopram with the high affinity primary site, and on its dissociation from the 5-HT transporter, via an allosteric mechanism .
    (R)-Citalopram oxalate
  • HY-W013378S2
    Carbamazepine 10,11-epoxide-13C,d2

    		Endogenous Metabolite Others
    Carbamazepine 10,11-epoxide- 13C,d2 is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a 13C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures[1][2].
    Carbamazepine 10,11-epoxide-13C,d2
  • HY-17032
    Indeloxazine

    (rac)-AS1069562 free base; YM-08054 free base

    		 Endogenous Metabolite Neurological Disease
    Indeloxazine ((rac)-AS1069562 free base) is a brain active compound with anti-amnesic activity. Indeloxazine significantly prolonged the step latency in senescence accelerated mice (SAM-P/8/Ta), indicating that it has a promoting effect on brain function. Indeloxazine has a broader pharmacology than piracetam and exhibits stronger anti-amnesic activity. Indeloxazine has also been used as an anticonvulsant compound, further supporting its potential use in neuroprotection and behavioral improvement .
    Indeloxazine
  • HY-103506
    NNC-711

    NO-711 hydrochloride

    		 GABA Receptor Neurological Disease
    NNC-711 (NO-711 hydrochloride) is a potent and selective inhibitor of GAT-1 (GABA transporter 1) with IC50 values of 0.04, 0.38, 171, 1700, 349, 622 μM for human GAT-1, rat GAT-1, rGAT-2, hGAT-3, rGAT-3, hBGT-3, respectively. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity .
    NNC-711
  • HY-110289R
    (R)-Citalopram (oxalate) (Standard)

    		Serotonin Transporter 5-HT Receptor Neurological Disease
    (R)-Citalopram (oxalate) (Standard) is the analytical standard of (R)-Citalopram (oxalate). This product is intended for research and analytical applications. (R)-Citalopram oxalate is an anticonvulsant, antidepressant and muscle relaxant. (R)-Citalopram oxalate is at least 20-fold weaker than S-citalopram (Escitalopram; HY-14258) as inhibitor of the 5-HT transporter (SERT). (R)-Citalopram oxalate functionally antagonises S-citalopram in vivo and in vitro. (R)-Citalopram oxalate has an effect on the association of Escitalopram with the high affinity primary site, and on its dissociation from the 5-HT transporter, via an allosteric mechanism .
    (R)-Citalopram (oxalate) (Standard)
  • HY-101392
    Harmane
    1 Publications Verification

    		 Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor Neurological Disease Inflammation/Immunology
    Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
    Harmane
  • HY-101392A
    Harmane hydrochloride

    		Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor Neurological Disease Inflammation/Immunology
    Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
    Harmane hydrochloride
  • HY-W700834
    Harman-d3

    		Isotope-Labeled Compounds Neurological Disease Inflammation/Immunology
    Harman-d3 is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
    Harman-d3
  • HY-W777360
    Harman-13C2,15N

    		Isotope-Labeled Compounds Adrenergic Receptor Monoamine Oxidase nAChR Opioid Receptor Imidazoline Receptor GABA Receptor Neurological Disease Inflammation/Immunology
    Harman- 13C2, 15N is 13C and 15N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
    Harman-13C2,15N

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: